Table 2 Comparison of patients in the treatment-naïve and pre-treated groups who were treated with a fixed-dosing intravitreal aflibercept regimen

BCVA at 12 months from baseline

(ETDRS letters)

76.36±6.59

Δ =9.78 letters

p= 0.005^a

64.46±14.61

Δ = 0 letters

p= 1.000^a

0.004^b

Retinal thickness at 12 months from baseline (um)

243.55±162

Δ = 218.45

p= 0.000^a

303.69±139

Δ = 52.39

p= 0.23^a

0.009^b

Number and Proportion of patients with complete polyp regression at month 12 n (%)

5 (41.6%)

5 (38.4%)

0.87^c

Number and Proportion of patients with dry retina at month 12 n (%)

8 (67%)

7 (53.8%)

0.51^c